Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
Work on discovery and development of new and specific PARP1 inhibitors to overcome hematological toxicity continues: “Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 Inhibitors” https://lnkd.in/g-87d783 #oncology #therapeutics #drugdiscovery